Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) announced that its Phase 3 EMANATE trial evaluating setmelanotide for rare genetic obesity conditions failed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE